Hypersensitivity following Retreatment with Carboplatin a Decade after Completion of Primary Platinum-Based Chemotherapy

Abstract

The relatively rapid development of a platinum-associated hypersensitivity reaction in an ovarian cancer patient receiving second-line chemotherapy more than a decade following her last course of primary platinum-based chemotherapy demonstrates that the prolonged persistence of immune cells recognizing platinum after sensitization has been established.

Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab

“…Lower IRR rates are reported for other monoclonal antibodies (Amgen, Inc., 2014;Bristol-Myers Squibb Company, 2013;Chung, 2008;Genentech, Inc., 2014a, 2014cPlosker & Figgitt, 2003). IRR rates with monoclonal antibodies are similar to those reported for taxanes (20%-41% [grade 3 or greater, 2%-10%]) (Bristol-Myers Squibb Company, 2011; Sanofi-Aventis, 2013) and platinum agents (2%-16% [grade 3 or greater, 1%-4%]) (Brandi et al, 2003;Bristol-Myers Squibb Company, 2004;Chung, 2008;Markman et al, 1999;Polyzos et al, 2001;Saif, 2006;Siu, Chan, & Au, 2006;Teva Pharmaceuticals, 2012). Similar to monoclonal antibodies, most taxane IRRs occur during the first infusion, whereas reactions to platinum agents typically occur after six or more infusions.…”

Biphasic and Delayed Hypersensitivity Reactions

“…In the oncology setting, platinum agents are responsible for the most frequently seen delayed HSRs. In most cases, oxaliplatin and carboplatin are the offending agents (Williams & Markman, 2009). The incidence of HSRs increases as patients receive multiple cycles of therapy.…”